Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 15 Oct
Source: Bse
Advanced Enzyme Technologies Limited (ADVENZYMES)
Micro CapPharma stocks · Micro cap · NSE
Advanced Enzyme Technologies Ltd. is a research-driven global leader in manufacturing enzymes and probiotics. It provides eco-safe solutions for human & animal nutrition, baking, fruit & vegetable processing, brewing, grain processing, protein modification, dairy, specialty applications, and textile processing, aiming to replace chemicals with enzymatic solutions.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals14 Oct 2026 · screener
Latest result16 Aug, 12:54 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
52Neutralfull bear SMA stack · SMA20 -6.4% / mo · RSI oversold · MACD − · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
ADVENZYMESD candles · FIT view-12.4%Latest close ₹262.00 on 2026-10-19
Bar
-2.6%
RSI
30
MACD hist
-0.41
52W pos
6%
2026-10-19O ₹269.00H ₹269.70L ₹258.00C ₹262.00Vol 2.2L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ADVENZYMESNifty PharmaNifty 500
- ADVENZYMES
- -17.9%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -12.3 pp
Chart stats
19 Oct 2026- From 52W high
- -37.5%
- 52W range position
- 6%
- ATR (14)
- 3.1%
- Volume vs 20D
- 1.02x
- Avg traded value
- ₹6 Cr
- 20D price channel
- ₹258 - ₹302.7
₹419
₹252 - ₹419
₹8.2
Latest completed session
20-session average
21.4% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE47
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +2.1% · PAT -2.5% YoY
Technical
Neutral52
Price trend and sector-relative-strength timing.
Valuation
Legacy model-119.3%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence80
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100PAT -3% YoY · margin compression · Rev +2% YoY
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹190 Cr | +2.1% | -6.4% |
| EBITDA | ₹51 Cr | -8.9% | -19.0% |
| Operating margin | 27.0% | -300 bps | -400 bps |
| PAT | ₹39 Cr | -2.5% | -13.3% |
| PAT margin | 20.5% | -98 bps | -164 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 19.00
- P/B
- 1.83
- EV/EBITDA
- 11.46
- Market Cap
- 2994.00Cr
Profitability
- ROE
- 10.20%
- ROCE
- 14.00%
- ROA
- 9.38%
- Dividend Y
- 2.00%
Growth (CAGR)
- Revenue 5Y
- 8.00%
- EPS 5Y
- 1.00%
- Revenue 3Y
- 11.00%
- EPS 3Y
- 12.00%
Balance Sheet
- Debt/Equity
- 0.02
- Interest Coverage
- 112.00×
- Altman Z
- 8.36
- Book Value
- 146.00
Cash Flow
- FCF Yield
- 2.84%
- FCF Positive Y
- 11/5
- OCF
- 157.00 Cr
- EPS TTM
- 14.82
Shareholding
- Promoter Hold
- 43.25%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 9%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 746+17.1% vs prev
Net Profit
₹ CrLatest: 174+29.9% vs prev
Return on Equity
%Latest: 10.7+12.9% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 30. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~6.8% over last month) — short-term momentum negative.
- RSI(14) at 30 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
40
RS percentile
Stage 4 Downtrend
1M return
-9.0%
3M return
-17.9%
6M return
-12.4%
1Y return
-15.0%
RS 1D
-2
RS 20D
+1
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 17.6% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -0.7%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 84.37-0.86%
RS vs Nifty 50084
Valuation & peers
U-Score 47 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 47 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation10/30
Growth9/25
Quality2/20
Balance Sheet12/15
Cash Flow8/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
47
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
47/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 12/15 to the score.
- Cash flow contributes 8/10 to the score.
Main drags
- Fair-value margin of safety is negative at -119.3%.
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Valuation is weaker at 10/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
19.0
PB
1.8
EV/EBITDA
11.5
ROE
10.2%
ROCE
14.0%
FCF Yield
2.8%
Debt/Equity
0.0
MoS
-119.3%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
47
Previous: 46 (+1)
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
-119.3%
Previous: -119.3%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
46
46
46
46
46
46
46
46
46
46
46
46
Factor attribution
Valuation
10+1
was 9
Modelled fair value
Graham Number
₹220.64
-18.7% MoS
Growth-justified P/E
8.1
Growth-justified Value
₹119.45
-119.3% MoS
PEG
11.88
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
AARTIDRUGS
Micro
Aarti Drugs Limited
Pharmaceuticals
match 137
36
19.4
13.4%
-321%
WATCHLIST
WINDLAS
Small
Windlas Biotech Limited
Pharmaceuticals
match 135
48
31.6
12.2%
+36%
FAIR VALUE
FERMENTA
Small
Fermenta Biotech Limited
Pharmaceuticals
match 133
47
30.0
16.4%
-38%
FAIR VALUE
ALEMBICLTD
Small
Alembic Limited
Pharmaceuticals
match 132
58
8.4
13.0%
-21%
FAIR VALUE
INDSWFTLAB
Small
Ind-Swift Laboratories Limited
Pharmaceuticals
match 132
34
51.5
4.0%
-16%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-06-08T06:23:01.891Z
Management commentary snapshot
ADVENZYMES reported strong Q4 FY26 results with Revenue up 22% YoY to 2,034 mn, EBITDA up 39% YoY to 632 mn, and PAT up 69% YoY to 453 mn. For FY26, Revenue grew 17% YoY to 7,458 mn, EBITDA 18% YoY to 2,291 mn, and PAT 30% YoY to 1,736 mn, driven by broad-based segment growth.
The company delivered robust financial performance in Q4 and FY26, with significant YoY and QoQ growth in revenue and profitability. Strategic focus on R&D, geographical expansion, and inorganic growth, coupled with strong segment performance, supports the investment thesis.
Current business mix
Revenue by Segment (Q4 FY26)
Latest issuer-disclosed distribution across 4 reported categories.
Human Nutrition63.0%
Industrial Bio-Processing16.0%
Animal Nutrition12.0%
Specialized Manufacturing9.0%
Growth engines
Human Nutrition Segment
Contributed 63% to Q4 FY26 revenue, grew 24% YoY to 1,281 mn, and 33% QoQ.
Animal Nutrition Segment
Grew 19% YoY in Q4 FY26 to 250 mn; 25% YTD in FY26 to 946 mn.
Industrial Bio-Processing (Food)
Food business grew 20% YoY in Q4 FY26 to 276 mn.
Specialized Manufacturing Segment
Grew 17% YoY in Q4 FY26 to 180 mn; 23% YTD in FY26 to 662 mn.
Capacity and execution
Manufacturing Units
Operates 9 manufacturing units (8 in India, 1 in USA).
Fermentation Capacity
Total fermentation capacity of 500 m3.
Solar Power Plant
Successfully commissioned a 510kW solar power plant.
Tailwinds
Global Enzymes Market Growth
Expected to grow at a CAGR of 14.12% from CY 2024-29.
Global Probiotics Market Growth
Expected to grow at a CAGR of 7.80% till 2029.
Shift to Eco-friendly Solutions
Company's mission to replace traditionally used chemicals with eco-friendly enzymatic solutions.
Headwinds
Americas Revenue Decline
Revenue from Americas de-grew 11% YoY in Q4 FY26 and 7% YTD in FY26.
Europe Revenue Decline
Revenue from Europe de-grew 7% YoY in Q4 FY26.
Industrial Bio-Processing (Non-Food) Stagnation
Non-Food business de-grew 1% YoY in Q4 FY26 and remained flat YTD in FY26.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
Q4 FY26 results show strong YoY growth across revenue and profitability, indicating robust performance compared to the previous year. QoQ growth also shows sequential momentum, especially in revenue and EBITDA, suggesting continued operational strength.
Sector KPIs management disclosed
EBITDA Margin
Q4 FY26: 31%; FY26: 31%
PAT Margin
Q4 FY26: 22%; FY26: 23%
Domestic Revenue Growth (India)
Q4 FY26: +51% YoY to 1,061 mn; FY26: +28% YoY to 3,727 mn
Americas Revenue Growth
Q4 FY26: -11% YoY to 573 mn; FY26: -7% YoY to 2,192 mn
Management forward view
Continued R&D Investment
Focus on identifying product gaps and developing new enzymes, probiotics & solutions.
Broaden Geographical Presence
Build strategic partnerships in key markets for focus segments.
Inorganic Expansion Strategy
Acquisition of key technologies, competencies, skill-sets, client relationships & businesses.
Bio-Catalysis for API Manufacturers
Developing enzymatic solutions for API manufacturers; products under advanced trial stages.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Americas Revenue Growth | -11% YoY in Q4 FY26. | Reversal of de-growth trend and return to positive growth. |
| Industrial Bio-Processing (Non-Food) Growth | -1% YoY in Q4 FY26. | Improvement in growth trajectory and contribution to segment. |
| API Bio-catalysis Commercialization | Products under advanced trial stages. | Successful commercialization and revenue contribution from API bio-catalysis. |
| New Probiotics Product Launches | Plans to introduce more probiotics products. | Specific product launches and market acceptance in human and animal nutrition. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
80Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 90th percentile of the scored universe and 87th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
176 docs text-extracted · 72 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
90th percentile
overall median 67 · Pharma: 87th pctile, median 70 · Micro: 81st pctile, median 73
Evidence depth
Financial-only
176 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
79
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 2.6%.
- ▸11 years of positive FCF.
- ▸Debt/equity is 0.02.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Advanced Enzyme Technologies Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 14 Oct
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 13 Oct
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 9 Oct
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 5 Oct
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 1 Oct
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 30 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 28 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 25 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 23 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 18 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 17 Sep
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.